Kalaris Therapeutics, Inc. financial data

Symbol
KLRS on Nasdaq
Location
628 Middlefield Road, Palo Alto, CA
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2025 - Nov 12, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 603 % -58.8%
Debt-to-equity 281 %
Return On Equity -290 % -258%
Return On Assets -63.6 % +12.4%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 18.7M shares -83.8%
Common Stock, Shares, Outstanding 18.7M shares -83.8%
Entity Public Float 58.8M USD -77.8%
Common Stock, Value, Issued 2K USD -81.8%
Weighted Average Number of Shares Outstanding, Basic 18.7M shares +1283%
Weighted Average Number of Shares Outstanding, Diluted 18.7M shares +1283%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense -5.26M USD -114%
General and Administrative Expense 51.3M USD +270%
Operating Income (Loss) -56.2M USD +47.5%
Nonoperating Income (Expense) 847K USD
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -44.3M USD -5.23%
Income Tax Expense (Benefit) 0 USD
Net Income (Loss) Attributable to Parent -45.1M USD +57.8%
Earnings Per Share, Basic 19 USD/shares +97.7%
Earnings Per Share, Diluted 19 USD/shares +97.7%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 42.4M USD +2116%
Cash, Cash Equivalents, and Short-term Investments 118M USD -35.7%
Assets, Current 78.2M USD -36.2%
Property, Plant and Equipment, Net 673K USD -28.6%
Operating Lease, Right-of-Use Asset 1.52M USD
Other Assets, Noncurrent 976K USD
Assets 81.2M USD -33.8%
Accounts Payable, Current 494K USD +869%
Accrued Liabilities, Current 4.99M USD -50.5%
Liabilities, Current 6.07M USD +330%
Operating Lease, Liability, Noncurrent 1.17M USD
Liabilities 39.3M USD +2684%
Accumulated Other Comprehensive Income (Loss), Net of Tax 6K USD
Retained Earnings (Accumulated Deficit) -150M USD +78.5%
Stockholders' Equity Attributable to Parent 41.9M USD
Liabilities and Equity 81.2M USD -33.8%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -7.44M USD -64.6%
Net Cash Provided by (Used in) Financing Activities 107M USD +1530%
Net Cash Provided by (Used in) Investing Activities 40M USD -4.13%
Common Stock, Shares Authorized 300M shares 0%
Common Stock, Shares, Issued 18.7M shares -83.8%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 99.8M USD +4751%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 42.9M USD +2142%
Deferred Tax Assets, Valuation Allowance 157M USD -13.5%
Deferred Tax Assets, Gross 158M USD -12.7%
Operating Lease, Liability 1.55M USD
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -11.9M USD +68.8%
Lessee, Operating Lease, Liability, to be Paid 2.23M USD
Property, Plant and Equipment, Gross 1.92M USD -0.83%
Operating Lease, Liability, Current 376K USD
Lessee, Operating Lease, Liability, to be Paid, Year Two 342K USD
Lessee, Operating Lease, Liability, to be Paid, Year One 335K USD
Operating Lease, Weighted Average Discount Rate, Percent 0.13 pure
Deferred Income Tax Expense (Benefit) 0 USD
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 682K USD
Lessee, Operating Lease, Liability, to be Paid, Year Three 349K USD
Deferred Tax Assets, Operating Loss Carryforwards 100M USD +85.8%
Preferred Stock, Shares Issued 0 shares
Current Income Tax Expense (Benefit) -265K USD -126%
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 0 USD
Lessee, Operating Lease, Liability, to be Paid, Year Four 356K USD
Operating Lease, Payments 0 USD -100%
Additional Paid in Capital 192M USD -76.5%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 86K USD -81.5%
Deferred Tax Assets, Net of Valuation Allowance 1.86M USD +273%
Share-based Payment Arrangement, Expense 27.3M USD +158%
Interest Expense 1.44M USD +1750%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%